Juvenile Idiopathic Arthritis

Living under COVID-19 lockdown was associated with a higher rate of joint inflammation in children with juvenile idiopathic arthritis, according to data from an Italian cohort published in Arthritis Care & Research.

There is significant variation in the patterns of methotrexate use prior to initiating etanercept in patients with juvenile idiopathic arthritis, according to registry data published in Pediatric Rheumatology.

Biologic initiation in children hospitalized with new-onset systemic juvenile idiopathic arthritis increased significantly from 2008 to 2019, reaching 40% between 2017 and 2019, and may be linked with reduced glucocorticoid use, according to data.

Approximately 70% of patients with juvenile idiopathic arthritis who are re-treated with etanercept achieve inactive disease status 12 months after receiving the second course, according to data published in Arthritis Research & Therapy.

Parents reported that two-thirds of children with juvenile idiopathic arthritis demonstrate drug side effects that impact their quality of life within 1 year of diagnosis, according to data published in Arthritis Care & Research.

Subcutaneous tocilizumab provides similar exposure and risk-benefit profiles as intravenous tocilizumab in patients with systemic juvenile idiopathic arthritis, according to findings published in Rheumatology.

Uveitis has a “significant impact” on visual functioning and vision-related quality of life among children with juvenile idiopathic arthritis, according to data published in Arthritis Care & Research.

Patients with polyarticular-course juvenile idiopathic arthritis achieved high-level disease control for up to 2 years when treated with tocilizumab, according to data published in Arthritis & Rheumatology.

The FDA has approved Simponi Aria for the treatment of polyarticular juvenile idiopathic arthritis in patients aged 2 years and older, while also expanding its psoriatic arthritis indication for this patient population, according to a press release from Janssen.

The FDA has approved Xeljanz in tablet and oral formulations for the treatment of polyarticular course juvenile idiopathic arthritis in patients aged 2 years and older, according to a press release from Pfizer.